With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too
Executive SummaryWith a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has
You may also be interested in...
Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.
Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.